Butyrate prevents visceral adipose tissue dysfunction and metabolic alterations in a mouse model of Friedreich's ataxia
Friedreich's ataxia (FA) is a rare neurodegenerative disease caused by the expansion of intronic trinucleotide repeat GAA from 8-33 repeats to &gt;90 repeats in the FXN gene encoding frataxin protein (FXN). Apart from manifesting neurodegenerative signatures, FA patients are at higher risk to developing type 2 diabetes (T2D) and cardiomyopathy than general population. Efficient therapeutics to definitively cure FA have been not identified yet. Supplementation with  butyrate ameliorates body metabolism and increases insulin sensitivity.